赛托生物(300583.SZ)：糠酸莫米松收到化学原料药上市申请批准通知书

Core Viewpoint - Saito Bio (300583.SZ) announced that its subsidiary, Shandong Sry Pharmaceutical Co., Ltd., has received approval from the National Medical Products Administration for the marketing application of Mometasone Furoate, which has strong anti-inflammatory properties and is used in inhalers and topical skin medications [1] Group 1: Product Approval - The approval pertains to Mometasone Furoate, which can be used as an inhalant in combination with β2-adrenergic agonists and/or long-acting acetylcholine receptor antagonists, primarily for asthma treatment [1] - As a topical medication, Mometasone Furoate is indicated for conditions such as eczema, neurodermatitis, atopic dermatitis, and skin pruritus [1]